4.0	•	The state of the s	1642
OIP	Ē	08-25	
	CIE	Docket No.	. 13761-739 E
AUG 2 4	[X] Chysuant to 37 C.F.R. § 1.8, I here indicated below in an envelope [ ] Pursuant to 37 C.F.R. § 1.6(d), I he	Certificate of Mailing/Transmission (37 C.F.R. § 1.8(a)):  eby certify that this paper and all enclosures are being deposited with the United States Postal Service as first e addressed to the Assistant Commissioner for Patents, Washington D.C. 20231.  ereby certify that this paper and all enclosures are being sent via ficsimile on the date indicated below to the acsimile No.  Name of Person Certifying:  Printed Name:  Laer Barrett	t class mail on

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Lenz, Heinz-Josef

Assignee:

University of Southern

California

Filing Date:

11/15/2000

Examiner:

Unassigned

11-1

Serial No.:

09/715,764

Group Art Unit: 1645

: 1645

Title:

GENOMIC POLYMORPHISM FOR PREDICTING THERAPEUTIC

**RESPONSE** 

Assistant Commissioner for Patents Washington, D.C. 20231

# **SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with 37 C.F.R. § 1.56, the references listed on the attached Form PTO-1449 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application.

## I. Timing of the Information Disclosure Statement:

This Information Disclosure Statement is filed:

With the new patent application submitted herewith (37 C.F.R. § 1.97(a)).
Within three months after the filing date of the application or within three months after the date of entry of the national stage of a PCT application as set forth in 37 C.F.R. § 1.491.
Before the mailing date of a first Office action on the merits. In the event, however, that an Office Action has crossed in the mail with this Information Disclosure Statement, the Commissioner is hereby authorized to charge Deposit Account No. 50-1192, Docket No. 13761-739 for any fees required pursuant to 37 C.F.R. §§ 1.17(p) or 1.17(i)(1).

This Informat	ion Disclosure Statement is filed:		
	After the first Office Action and more than three months after the application's filing date; or PCT national stage date of entry filing but, as far as is known to the undersigned, prior to the mailing date of either a final rejection or a notice of allowance, whichever occurs first, and the Commissioner is hereby authorized to charge Deposit Account No. 50-1192, Docket No. 13761-0739, for the fee (\$180) set forth in 37 C.F.R. § 1.17(p) and any additional required fees.		
This Informat	ion Disclosure Statement is filed:		
	After the mailing date of either a final rejection or a notice of allowance, whichever occurred first, and is accompanied by the fee (\$180.00) set forth in 37 C.F.R. § 1.17(i)(1) and a certification as specified in 37 C.F.R. § 1.97(e), as checked below. This document is to be considered as a petition requesting consideration of the Information Disclosure Statement.		
The undersign	ned certifies that:		
	Each item of information contained in the Information Disclosure Statement was cited in a communication mailed from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.		
	No item of information contained in this information disclosure statement was cited in a communication mailed from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.		
II. Copies of the Cited Items:			
	Copies of all of the items listed on the attached Form PTO-1449 are enclosed.		
	Copies of only the following items listed on the attached Form PTO-1449 are enclosed:		
	Copies of those items which are marked with an asterisk (*) in the attached Form PTO-1499 are not supplied because they were previously cited by or submitted to the Patent Office in a prior Application No, filed and relied upon in this application for an earlier filing date under 35 U.S.C § 120. See 37 C.F.R. § 1.98(d).		

$\boxtimes$	Copies of those items which are marked with an asterisk (**) in the attached Form
	PTO-1499 were cited in a foreign examination report in a related case. A copy of
	the search report and the cited references not already of record in this application
	are attached hereto.

#### III. Concise Explanation of Relevance:

A concise explanation of relevance of the items listed on Form PTO-1449 is not given.
A concise explanation of relevance of [some of] the items listed on Form PTO-1449 is in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references (copy attached).

#### IV. Conclusion:

Citation of the above documents shall not be construed as:

- 1. an admission that the documents are necessarily prior art with respect to the instant invention;
- 2. a representation that a search has been made, other than as described above; or
- 3. an admission that the information cited herein is, or is considered to be, material to patentability as defined in § 1.56(b).

It is respectfully requested that the Examiner indicate consideration of the cited references by returning a copy of the attached form PTO 1449 with initials or other appropriate marks.

The Commissioner is hereby authorized to charge Deposit Account No. 50-1192, Docket No. 13761-739 for any additional fees required in connection with the filing of this Information Disclosure Statement.

DATE: August 22, 2001

Respectfully submitted

Registration No.: 43,999

McCutchen, Doyle, Brown & Enersen, LLP

Three Embarcadero Center San Francisco, California 94111

Telephone: (415) 393-2000

Telefax: (415) 393-2286